Cancer Genetics – News and Features

New research may provide a new biological target for immunotherapies designed to destroy spreading cancer cells that are often markers for worsening disease.

A identified 813 potential cancer driver genes via splicing, expanding targets beyond traditional mutation-centric models. Using the "spotter" algorithm, researchers found significant non-overlap with existing mutation databases.

A study reveals that aberrant activation of the MYC oncoprotein drives significant changes in the prostate cancer microenvironment. Researchers found MYC's role in transforming the tissue from inflammatory to immunosuppressive.

Researchers from Duke-NUS discovered that the protein Gα13 acts as a tumor suppressor in estrogen receptor-positive (ER+) breast cancer, contradicting previous views of its cancer-promoting role.

Researchers have identified specific white blood cells (TREM2+ macrophages) that help resolve MASH, a serious liver condition. These cells play a crucial role in reducing inflammation and fibrosis, potentially aiding recovery.

Corn, a staple food crop consumed by billions of people and animals worldwide, is frequently contaminated by the fungal toxin aflatoxin B1, a highly potent carcinogen, but X-ray irradiation could help.

PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the drugs eventually stop working and the cancer returns. A new study in mice now suggests that a second cancer drug may be able to prevent or delay relapse.

In the most comprehensive study of its kind, researchers compared epigenetic changes across the genome in young adults who vaped, smoked or did not use nicotine products, finding a tumor-suppressor gene among the top affected genes in smokers.

Scientists have taken a fresh approach to finding a way to target neuroblastoma, the most common solid tumor of infancy. Their novel gene target could offer hope for finding alternative treatments with fewer long-term side effects.

A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity.